Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 1

Status

Recruiting 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 27INDUSTRY 5OTHER_GOV 4

Study Type

Interventional 5

Sponsor

Cancer Type

Head & Neck 5

Conditions

Breast Neoplasms 150Colorectal Neoplasms 82Stomach Neoplasms 77Neoplasms 35Neoplasm Metastasis 35Pancreatic Neoplasms 25Triple Negative Breast Neoplasms 22Parkinson Disease 4, Autosomal Dominant Lewy Body 16Adenocarcinoma 13Esophageal Neoplasms 12Carcinoma, Non-Small-Cell Lung 11Colonic Neoplasms 10Biliary Tract Neoplasms 10Rectal Neoplasms 9Carcinoma, Hepatocellular 9Brain Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Adenocarcinoma Of Esophagus 7Solid Tumor 6Ovarian Neoplasms 6Cholangiocarcinoma 6Nasopharyngeal Carcinoma 5Gastrointestinal Neoplasms 5Esophageal Squamous Cell Carcinoma 5Recurrence 4Nasopharyngeal Neoplasms 4Advanced Solid Tumors 4Sarcoma 3Melanoma 3Head and Neck Neoplasms 3

Interventions

Gemcitabine 12Cisplatin 11pembrolizumab 6Docetaxel 5Capecitabine 5camrelizumab 4Injections 4toripalimab 3spartalizumab 3penpulimab 2famitinib 2SHR-1701 2Carboplatin 218-O-demethylcervinomycin A2 2tislelizumab 1icotinib 1donafenib 1cc-486 1Valganciclovir 1Radiotherapy, Intensity-Modulated 1Quality of Life 1Pemetrexed 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Medicare Part B 1Ipilimumab 1Immunotherapy 1Fluorouracil 1Drug Therapy 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Nasopharyngeal Carcinoma × Capecitabine × Clear all
NCT06118333 2026-04-17

A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Active not recruiting
386 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT05126719 2026-02-06

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Shanghai Miracogen Inc.

Phase 2 Active not recruiting
238 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Recurrence

NCT06976190 2026-01-20

Magic-C002

Shanghai Miracogen Inc.

Phase 3 Recruiting
446 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Recurrence

NCT06629597 2025-02-10

A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 3 Recruiting
400 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT05717764 2023-02-08

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Phase 3 Not yet recruiting
500 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡